|Other Names||Carbonyl reductase [NADPH] 1, 15-hydroxyprostaglandin dehydrogenase [NADP(+)], NADPH-dependent carbonyl reductase 1, Prostaglandin 9-ketoreductase, Prostaglandin-E(2) 9-reductase, CBR1, CBR, CRN|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7563b was selected from the C-term region of human CBR1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Synonyms||CBR, CRN, SDR21C1|
|Function||NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Carbonyl reductase 1 (CBR1)is one of several monomeric,NADPH-dependent oxidoreductases having wide specificity for carbonyl compounds. This enzyme is widely distributed in human tissues.
Colombe,L.,Exp. Dermatol. 16 (9), 762-769 (2007)Lakhman,S.S.,Mol. Pharmacol. 72 (3), 734-743 (2007)Gonzalez-Covarrubias,V.,Drug Metab. Dispos. 35 (6), 973-980 (2007)
If you have any additional inquiries please email technical services at email@example.com.